107. Juvenile idiopathic arthritis Clinical trials / Disease details
Clinical trials : 447 / Drugs : 297 - (DrugBank : 57) / Drug target genes : 52 - Drug target pathways : 146
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03301883 (ClinicalTrials.gov) | April 26, 2018 | 21/9/2017 | A Study of Tocilizumab in Chinese Participants With Systemic Juvenile Idiopathic Arthritis (sJIA) | A Phase IV, Multicenter, Single-Arm, Open-Label Study to Assess the Efficacy and Safety of Tocilizumab in Chinese Patients With Systemic Juvenile Idiopathic Arthritis | Juvenile Idiopathic Arthritis | Drug: Tocilizumab;Drug: NSAIDs;Drug: CSs;Drug: MTX | Hoffmann-La Roche | NULL | Completed | 2 Years | 17 Years | All | 62 | Phase 4 | China |